Integra LifeSciences Holdings Corp. (NASDAQ:IART) hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $85.43 and last traded at $85.14, with a volume of 69,280 shares. The stock had previously closed at $84.60.

Several equities research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Integra LifeSciences Holdings Corp. from a “hold” rating to a “buy” rating and set a $79.00 price target for the company in a research note on Monday, May 2nd. Barclays PLC raised their price objective on shares of Integra LifeSciences Holdings Corp. from $70.00 to $74.00 and gave the stock an “equal weight” rating in a report on Thursday, April 28th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Integra LifeSciences Holdings Corp. in a report on Thursday, April 28th. Jefferies Group raised their price objective on shares of Integra LifeSciences Holdings Corp. from $81.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, July 29th. Finally, Lake Street Capital raised their price objective on shares of Integra LifeSciences Holdings Corp. from $57.00 to $75.00 and gave the stock a “hold” rating in a report on Thursday, April 28th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $81.75.

The stock has a market capitalization of $3.17 billion and a PE ratio of 351.03. The company’s 50-day moving average is $79.53 and its 200 day moving average is $69.76.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last issued its earnings results on Thursday, July 28th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.76 by $0.03. The firm earned $249.30 million during the quarter, compared to the consensus estimate of $243.17 million. The company’s quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.79 EPS. On average, analysts anticipate that Integra LifeSciences Holdings Corp. will post $3.48 earnings per share for the current year.

In other news, VP Joseph Vinhais sold 972 shares of the business’s stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $73.36, for a total transaction of $71,305.92. Following the completion of the transaction, the vice president now directly owns 4,311 shares of the company’s stock, valued at $316,254.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Richard D. Gorelick sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $84.60, for a total transaction of $338,400.00. Following the transaction, the vice president now directly owns 9,702 shares of the company’s stock, valued at $820,789.20. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently added to or reduced their stakes in the stock. Comerica Bank boosted its position in Integra LifeSciences Holdings Corp. by 1.4% in the fourth quarter. Comerica Bank now owns 29,922 shares of the company’s stock valued at $1,965,000 after buying an additional 401 shares during the last quarter. New York State Common Retirement Fund boosted its position in Integra LifeSciences Holdings Corp. by 3.9% in the fourth quarter. New York State Common Retirement Fund now owns 26,400 shares of the company’s stock valued at $1,789,000 after buying an additional 1,000 shares during the last quarter. Rhumbline Advisers boosted its position in Integra LifeSciences Holdings Corp. by 6.6% in the fourth quarter. Rhumbline Advisers now owns 45,298 shares of the company’s stock valued at $3,070,000 after buying an additional 2,820 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Integra LifeSciences Holdings Corp. by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 928,232 shares of the company’s stock valued at $62,916,000 after buying an additional 11,339 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in Integra LifeSciences Holdings Corp. by 7.0% in the fourth quarter. Principal Financial Group Inc. now owns 196,763 shares of the company’s stock valued at $13,337,000 after buying an additional 12,904 shares during the last quarter.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.